Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China

Novartis announced new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab).